Propel Bio Management LLC Purchases 50,000 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Propel Bio Management LLC lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 60.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 133,259 shares of the company’s stock after buying an additional 50,000 shares during the period. Syndax Pharmaceuticals comprises 1.5% of Propel Bio Management LLC’s portfolio, making the stock its 13th largest holding. Propel Bio Management LLC owned about 0.16% of Syndax Pharmaceuticals worth $2,565,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after acquiring an additional 541 shares in the last quarter. Sei Investments Co. raised its stake in shares of Syndax Pharmaceuticals by 2.5% in the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after purchasing an additional 991 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Syndax Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after purchasing an additional 1,150 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at $27,000. Finally, Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the 3rd quarter worth about $30,000.

Analysts Set New Price Targets

Several equities analysts have issued reports on SNDX shares. JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. The Goldman Sachs Group raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Stifel Nicolaus boosted their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. UBS Group began coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. Finally, Bank of America lifted their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Trading Up 0.1 %

Syndax Pharmaceuticals stock opened at $16.74 on Tuesday. Syndax Pharmaceuticals, Inc. has a 12-month low of $15.00 and a 12-month high of $25.34. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -4.61 and a beta of 0.92. The firm has a 50 day moving average of $18.57 and a 200 day moving average of $19.93.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the business earned ($0.73) earnings per share. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.69 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).